Articles for tag: How to Invest, Investing, Stocks

March 7, 2025

Ron Finklestien

Is Now the Right Time to Invest in Gilead Sciences (GILD) Stock at Its 52-Week Peak?

Gilead Sciences Stock Reaches New Heights Amid Market Uncertainty Gilead Sciences GILD has achieved new 52-week highs even as the broader market has faced a sharp pullback recently. Along with Johnson & Johnson JNJ, the pharmaceutical company is among a select group of healthcare stocks that have reached impressive peaks. With shares trading at $117, Gilead has surged nearly +30% year-to-date, while major market indexes remain in the negative. Investors are keen to explore exposure in the medical sector during this period of economic uncertainty. Image Source: Zacks Investment Research   Leadership in the Medical Sector Gilead is known for

March 5, 2025

Ron Finklestien

Is Now the Right Time to Invest in Oklo After Their DOE Program Participation?

Oklo Inc. Joins DOE Program, Stock Performance Impresses Investors Oklo Inc. (OKLO) has recently become a participant in the U.S. Department of Energy (“DOE”) Voucher Program to evaluate and test advanced structural materials intended for its Aurora powerhouse. This initiative seeks to improve manufacturing efficiencies, fortify the supply chain, and accelerate Oklo’s commercial deployment of nuclear technologies. The program is managed by ENERGYWERX in collaboration with Oak Ridge National Laboratory and focuses on material validation for Oklo’s fast reactors. This partnership aims to enhance Oklo’s reputation for delivering scalable and cost-effective clean energy solutions, potentially attracting investors who target long-term

March 5, 2025

Ron Finklestien

Navigating Tesla’s Stock Amid Musk’s Political Decisions: Investor Strategies Ahead

Political Controversies Impact Tesla’s Sales and Stock Performance Tesla Inc. (TSLA) has long been associated with its dynamic CEO Elon Musk. His visionary leadership and business strategies transformed Tesla into a key player in the electric vehicle (EV) sector. Like Amazon revolutionizing retail and Netflix reshaping entertainment, Musk’s innovations led to excitement surrounding new car releases and significant stock price spikes. However, the landscape has shifted significantly. Currently, instead of headlines celebrating Tesla’s technological advancements, Musk’s growing entanglement in politics is drawing scrutiny. This shift has investors, including loyal Tesla fans, increasingly dissatisfied, with some even boycotting the brand. Once

March 4, 2025

Ron Finklestien

Is It Time to Invest in Johnson & Johnson (JNJ) for Future Gains?

Johnson & Johnson: A Key Player Amid Market Unrest Markets have experienced continued sell-offs this week as investors assess the implications of new tariffs and rising geopolitical tensions. In this context, Johnson & Johnson JNJ is emerging as a notable stock. The pharmaceutical leader reached 52-week highs of nearly $170 on Tuesday, marking a +16% increase year to date. With its defensive positioning, JNJ may be a promising opportunity for investors looking for growth. Image Source: Zacks Investment Research Diversification Strengthens J&J’s Position During periods of economic uncertainty, medical stocks often draw investor interest due to the consistent demand for

March 4, 2025

Ron Finklestien

BSX Stock Expected to Rise Following Acquisition Agreement with SoniVie Ltd.

Boston Scientific Announces Agreement to Acquire SoniVie Ltd. Boston Scientific, Inc. (BSX) has entered into a definitive agreement to acquire SoniVie Ltd., a privately-held medical device company known for its TIVUS Intravascular Ultrasound System. Boston Scientific currently holds a 10% stake in SoniVie and will pay approximately $360 million to acquire the remaining 90%. An additional $180 million will be contingent upon achieving certain regulatory milestones. The deal is anticipated to close in the first half of 2025, contingent upon customary closing conditions. Market Reaction to the Acquisition Announcement In response to the announcement, shares of Boston Scientific rose 1%,

February 28, 2025

Ron Finklestien

Chemed Reports Q4 Earnings Beat and Revenue Growth, Shares Rise Despite Margin Compression

Chemed Corporation Reports Strong Fourth Quarter Earnings Performance Chemed Corporation (CHE) has announced its fourth-quarter 2024 adjusted earnings per share (EPS) of $6.83, reflecting a year-over-year increase of 3.5%. This figure exceeded the Zacks Consensus Estimate by 0.5%. Find the latest EPS estimates and surprises on Zacks Earnings Calendar. The company also reported a GAAP EPS of $6.02, which is up 2% from the previous year. For the full year, Chemed’s adjusted EPS reached $23.13, representing a 13.9% increase from the previous year. Improved Revenue Performance In the fourth quarter, Chemed’s revenues increased by 9.2% year over year, reaching $640

February 27, 2025

Ron Finklestien

NVIDIA Stock Declines: Analyzing the Impact of Earnings Report

Nvidia’s Strong Results Face Share Pressure After Q4 Earnings With Nvidia’s (NVDA) quarterly release completed, the 2024 Q4 reporting cycle for the broader Mag 7 group has officially wrapped up. Most members of this elite club reported solid growth in both revenue and earnings, yet not all enjoyed a positive reaction from the market. Nvidia shares also experienced pressure following their earnings report. Over the past three months, the stock has declined roughly 2%, showing limited overall positivity during this period. Image Source: Zacks Investment Research This raises an important question: Were Nvidia’s earnings disappointing? Let’s analyze the results more

February 27, 2025

Ron Finklestien

Stock Under Pressure: A Closer Look at Graphic Packaging Holding Company (GPK)

Graphic Packaging Faces Earnings Challenges Amid Economic Headwinds Graphic Packaging Holding Company GPK is a sustainable packaging firm that has recently fallen short of earnings expectations and provided disappointing future guidance. This trend of declining earnings aligns with a broader economic slowdown coupled with persistent inflation. In early February, Graphic Packaging revised its earnings forecasts downward, demonstrating ongoing challenges in navigating today’s economic landscape. Understanding GPK Stock Graphic Packaging produces an array of essential paper packaging products, catering to clients in diverse sectors including food, beverages, personal care, and household goods. Their offerings feature folding cartons, cooking solutions, and service

February 25, 2025

Ron Finklestien

Identifying Top Performing Stocks to Invest in During Market Corrections

Wall Street Takes Caution Ahead of Nvidia Earnings: A Look at Strong Stocks to Buy As Nvidia prepares to announce its earnings on Wednesday, Wall Street has shifted into risk-off mode. Investors are selling a range of assets, including Bitcoin, Constellation Energy, and Tesla, in an effort to safeguard profits following a significant post-Trump election market surge. This swift selloff is affecting major momentum stocks and starting to ease the pressures of an overheated market. Check out the Zacks Earnings Calendar to stay ahead of important market developments. Fortunately, some stocks remain attractive options as they are still trading near

February 25, 2025

Ron Finklestien

“Why Now Is the Time to Invest in South Atlantic Bancshares (SABK) as It Approaches a Potential Bottom”

South Atlantic Bancshares (SABK) Might Be Ready for a Comeback The stock has dipped 6.5% in recent weeks, but a hammer chart pattern suggests a potential turnaround. Analysts are becoming increasingly optimistic about SABK’s future earnings, a strong sign for investors. Understanding the Hammer Chart Pattern The hammer chart pattern is a well-known tool in candlestick charting. It features a small candle body formed by a minor difference between the opening and closing prices, and a long lower wick that indicates a significant drop from the day’s low. The lower wick should be at least twice the length of the